: A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors

No strong warning signs right now. The score counts warning signs; it is not a prediction.

Why this score

Score over time

What counts as success

The trial's main goal(s), called the “primary outcome.”

• Dose escalation phase: Safety outcome evaluation - DLT, MTD/RP2D

  Measured over: From first dose to 30 days post the last dose

• Dose expansion phase (except EMC cohort): efficacy outcome evaluation - ORR based on the investigator's tumor assessment

  Measured over: very 6 weeks since Cycle1 Day 1, and every 12 weeks after Week 48, until disease progression or death or new anti-cancer therapy or loss of follow-up or withdrawal of consent

• Dose expansion phase (EMC cohort): efficacy outcome evaluation - ORR based on IRC's tumor assessment

  Measured over: Every 6 weeks since Cycle1 Day 1, and every 12 weeks after Week 48, until disease progression or death or new anti-cancer therapy or loss of follow-up or withdrawal of consent

• Fruquintinib monotherapy arm: efficacy outcome evaluation - ORR based on investigator's tumor assessment

  Measured over: Every 6 weeks since Cycle1 Day 1, and every 12 weeks after Week 48, until disease progression or death or new anti-cancer therapy or loss of follow-up or withdrawal of consent

Changes Tremor has spotted